{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:12:17Z","timestamp":1773706337350,"version":"3.50.1"},"reference-count":107,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AA&amp;MDSIF","award":["."],"award-info":[{"award-number":["."]}]},{"name":"Lilli Foundation","award":["."],"award-info":[{"award-number":["."]}]},{"name":"VeloSano Pilot Award","award":["."],"award-info":[{"award-number":["."]}]},{"name":"Vera and Joseph Dresner Foundation\u2013MDS","award":["."],"award-info":[{"award-number":["."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Acute myeloid leukemia (AML) is a heterogeneous group of clonal disorders characterized by abnormal proliferation of undifferentiated myeloid progenitors, impaired hematopoiesis, and variable response to therapy. To date, only about 30% of adult patients with AML become long-term survivors and relapse and\/or disease refractoriness are the major cause of treatment failure. Thus, this is an urgent unmet clinical need and new drugs are envisaged in order to ameliorate disease survival outcomes. Here, we review the latest therapeutic approaches (investigational and approved agents) for AML treatment. A specific focus will be given to molecularly targeted therapies for AML as a representation of possible agents for precision medicine. We will discuss experimental and preclinical data for FLT3, IDH1, BCL-2, Hedgehog pathway inhibitors, and epitherapy.<\/jats:p>","DOI":"10.3390\/cancers12020357","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T02:59:18Z","timestamp":1580957958000},"page":"357","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"first","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA"},{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4761","authenticated-orcid":false,"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Neuro-Oncohematology Unit, Fondazione Santa Lucia, Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.), 00143 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Visconte","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000486228","article-title":"Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001-2013","volume":"139","author":"Song","year":"2018","journal-title":"Acta Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcmd.2012.10.005","article-title":"A historical perspective on the development of the cytarabine (7days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3","volume":"50","author":"Lichtman","year":"2013","journal-title":"Blood Cells"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-018-0121-4","article-title":"Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies","volume":"8","author":"Tiong","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: A European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1053\/j.seminhematol.2018.09.001","article-title":"The emerging role of measurable residual disease detection in AML in morphologic remission","volume":"56","author":"Buccisano","year":"2019","journal-title":"Semin. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-16-0133","article-title":"Anticipating the \u201cSilver Tsunami\u201d: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States","volume":"25","author":"Bluethmann","year":"2016","journal-title":"Cancer Epidemiol Biomark. Preven."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1053\/j.seminoncol.2008.04.004","article-title":"Deregulation of signaling pathways in acute myeloid leukemia","volume":"35","author":"Scholl","year":"2008","journal-title":"Semin. Oncol."},{"key":"ref_11","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12032-017-0970-x","article-title":"FLT3-ITD and its current role in acute myeloid leukaemia","volume":"34","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions","volume":"16","author":"Baer","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2040620719827310","DOI":"10.1177\/2040620719827310","article-title":"Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia","volume":"10","author":"Short","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11864-017-0446-4","article-title":"What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?","volume":"18","author":"Pophali","year":"2017","journal-title":"Curr. Treat. Opt. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QCO.0000000000000611","article-title":"Azole antifungals and new targeted therapies for hematological malignancy","volume":"32","author":"Lindsay","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/cncr.28705","article-title":"Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations","volume":"120","author":"Alvarado","year":"2014","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.clml.2017.09.027","article-title":"The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with\u00a0FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase\u00a0I\/II Trial","volume":"17","author":"Swaminathan","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397","volume":"5","author":"Smith","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/cncr.31038","article-title":"Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3\/tyrosine kinase domain\/F691 mutation","volume":"124","author":"Fathi","year":"2018","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1200\/JCO.2016.34.15_suppl.7008","article-title":"Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"TPS7068","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7068","article-title":"Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML","volume":"37","author":"Stone","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3324\/haematol.2019.225862","article-title":"The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis","volume":"104","author":"Orlova","year":"2019","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","article-title":"Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment","volume":"31","author":"Ghiaur","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Al-Ghabkari, A., Perinpanayagam, M.A., and Narendran, A. (2019). Inhibition of PI3K\/mTOR pathways with GDC-0980 in pediatric leukemia: Impact on abnormal FLT-3 activity and cooperation with intracellular signaling targets. Curr. Cancer Drug Targets.","DOI":"10.2174\/1568009619666190326120833"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","article-title":"Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL","volume":"104","author":"Dumas","year":"2019","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12209","DOI":"10.1038\/s41598-019-48687-z","article-title":"The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia","volume":"9","author":"Cao","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1038\/bcj.2012.5","article-title":"Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies","volume":"2","author":"Kasper","year":"2012","journal-title":"Blood Cancer J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00432-016-2290-5","article-title":"Outcome of FLT3-ITD-positive acute myeloid leukemia: Impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment","volume":"143","author":"Fleischmann","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fonc.2019.00194","article-title":"Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors","volume":"9","author":"Han","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1038\/onc.2010.444","article-title":"Cancer-associated IDH mutations: Biomarker and therapeutic opportunities","volume":"29","author":"Yen","year":"2010","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm0311-291","article-title":"Metabolism unhinged: IDH mutations in cancer","volume":"17","author":"Prensner","year":"2011","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","article-title":"Ivosidenib: First Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-017-0813-2","article-title":"Enasidenib: First Global Approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1\/2 Study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543784.2017.1317745","article-title":"Therapeutic targeting of isocitrate dehydrogenase mutant AML","volume":"26","author":"Boddu","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2019-123920","article-title":"Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study","volume":"134","author":"Watts","year":"2019","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1078-0432.CCR-17-2796","article-title":"IDH1\/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1\/2-Mutant Inhibitors","volume":"24","author":"Molenaar","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11899-018-0464-8","article-title":"Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition","volume":"13","author":"Sharma","year":"2018","journal-title":"Curr. Hematol. Malign. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13000-019-0841-1","article-title":"BCL2 overexpression: Clinical implication and biological insights in acute myeloid leukemia","volume":"14","author":"Zhou","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","article-title":"Therapeutic targeting of acute myeloid leukemia stem cells","volume":"129","author":"Pollyea","year":"2017","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2002-06-1899","article-title":"Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia","volume":"101","author":"Marcucci","year":"2003","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First Global Approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/blood-2016-02-695312","article-title":"Evolution of acute myelogenous leukemia stem cell properties after treatment and progression","volume":"128","author":"Ho","year":"2016","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2011.606382","article-title":"Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: A multicenter phase I\/II study","volume":"53","author":"Jaekel","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_71","first-page":"1249","article-title":"Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)","volume":"130","author":"Tauchi","year":"2017","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/blood.V130.Suppl_1.813.813","article-title":"Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetocla x in Combina tion with MEK In hibitor Cobim etinib or MDM2 Inhibit or Idasanu tlin in Patients with Relapsed or Refractory (R\/R) AML","volume":"130","author":"Daver","year":"2017","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/35077219","article-title":"The Hedgehog and Wnt signalling pathways in cancer","volume":"411","author":"Taipale","year":"2001","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2019.04.005","article-title":"Hedgehog signaling inhibitors in solid and hematological cancers","volume":"76","author":"Cortes","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.30","article-title":"Hedgehog signaling in hematopoiesis","volume":"20","author":"Lim","year":"2010","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1046\/j.1523-1747.1998.00222.x","article-title":"Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome","volume":"110","author":"Aszterbaum","year":"1998","journal-title":"J. Invest. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/cas.13019","article-title":"Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells","volume":"107","author":"Fukushima","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1158\/1078-0432.CCR-14-1059","article-title":"Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects","volume":"21","author":"Wellbrock","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-19-0365","article-title":"FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2352-3026(15)00096-4","article-title":"Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: A phase 1 safety and pharmacokinetics study","volume":"2","author":"Martinelli","year":"2015","journal-title":"Lancet. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1158\/1078-0432.CCR-17-2824","article-title":"Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS","volume":"24","author":"Savona","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.2217\/fon-2019-0373","article-title":"Glasdegib plus intensive\/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials","volume":"15","author":"Cortes","year":"2019","journal-title":"Future Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jamadermatol.2015.5473","article-title":"Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma","volume":"152","author":"Ally","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fgene.2019.00133","article-title":"Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity","volume":"10","author":"Goldman","year":"2019","journal-title":"Front. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1200\/EDBK_199753","article-title":"Ultimate Precision: Targeting Cancer but Not Normal Self-replication","volume":"38","author":"Velcheti","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2019.05.013","article-title":"Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use","volume":"140","author":"Santini","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3324\/haematol.2013.099549","article-title":"Why methylation is not a marker predictive of response to hypomethylating agents","volume":"99","author":"Voso","year":"2014","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2040620718816698","DOI":"10.1177\/2040620718816698","article-title":"Epigenetic therapy combinations in acute myeloid leukemia: What are the options?","volume":"10","author":"Bewersdorf","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"150955","DOI":"10.1016\/j.soncn.2019.150955","article-title":"Novel Therapies in Acute Myeloid Leukemia","volume":"35","author":"Mukherjee","year":"2019","journal-title":"Semin. Oncol. Nur."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2018-99-116838","article-title":"Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)","volume":"132","author":"Sasaki","year":"2018","journal-title":"Blood"},{"key":"ref_95","unstructured":"Sekeres, M., and Steensma, D.P. (2020, January 14). Emerging Therapies in Clinical Trials for MDS Managing MDS. Available online: https:\/\/www.managingmds.com."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fcell.2019.00207","article-title":"Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects","volume":"7","author":"Gambacorta","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2019003262","article-title":"Epigenetic therapies in acute myeloid leukemia: Where to from here?","volume":"134","author":"Fennell","year":"2019","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1182\/blood-2019-124707","article-title":"CCS1477: A Novel Small Molecule Inhibitor of p300\/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma","volume":"134","author":"Brooks","year":"2019","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2019-124797","article-title":"An Open-Label Phase I\/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300\/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies","volume":"134","author":"Knurowski","year":"2019","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","article-title":"Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth","volume":"560","author":"Baell","year":"2018","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: Growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nature Rev. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/humu.10081","article-title":"The IARC TP53 database: New online mutation analysis and recommendations to users","volume":"19","author":"Olivier","year":"2002","journal-title":"Hum. Mut."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/gcc.20193","article-title":"Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile","volume":"43","author":"Schoch","year":"2005","journal-title":"Genes Chrom. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.2010.01557.x","article-title":"APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells","volume":"86","author":"Ali","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Maslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.H., and Bally, C. (2019). Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica.","DOI":"10.3324\/haematol.2019.218453"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1038\/bcj.2016.60","article-title":"An open-label phase I dose-finding study of APR-246 in hematological malignancies","volume":"6","author":"Deneberg","year":"2016","journal-title":"Blood Cancer J."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/2\/357\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:54:36Z","timestamp":1760172876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/2\/357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":107,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["cancers12020357"],"URL":"https:\/\/doi.org\/10.3390\/cancers12020357","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]}}}